0000000000656970

AUTHOR

Lise Lotte Gluud

showing 2 related works from this author

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct